2020
Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥65 Years of Age With a Low Ejection Fraction After Coronary Revascularization
Goldstein S, Li S, Lu D, Matsouaka R, Rymer J, Fonarow G, de Lemos J, Peterson E, Pokorney S, Wang T, Al-Khatib S. Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥65 Years of Age With a Low Ejection Fraction After Coronary Revascularization. The American Journal Of Cardiology 2020, 138: 26-32. PMID: 33068540, DOI: 10.1016/j.amjcard.2020.09.056.Peer-Reviewed Original ResearchMeSH KeywordsAftercareAge FactorsAgedAged, 80 and overCardiologyCoronary Artery BypassDeath, Sudden, CardiacDefibrillators, ImplantableFemaleHeart FailureHumansMaleMedicareMortalityMyocardial InfarctionMyocardial RevascularizationPatient ReadmissionPercutaneous Coronary InterventionProportional Hazards ModelsSex FactorsStroke VolumeTachycardia, VentricularUnited StatesVentricular FibrillationConceptsImplantable cardioverter-defibrillator implantationImplantable cardioverter-defibrillatorIn-hospital ventricular arrhythmiasLow ejection fractionAssociated with ICD implantationEjection fractionVentricular arrhythmiasICD implantationCoronary revascularizationCABG-treated patientsPCI-treated patientsAssociated with lower mortalityCardiology follow-upIn-hospital revascularizationAll-cause mortalityAssociated with higher likelihoodICD utilizationHeart failure readmissionHeart failureYear of revascularizationCardioverter-defibrillatorRevascularization strategyMedicare claimsRevascularizationPatients
2019
Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial)
Goldstein S, Green J, Huber K, Wojdyla D, Lopes R, Alexander J, Vinereanu D, Wallentin L, Granger C, Al-Khatib S. Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial). The American Journal Of Cardiology 2019, 124: 1406-1412. PMID: 31474328, PMCID: PMC7194994, DOI: 10.1016/j.amjcard.2019.07.046.Peer-Reviewed Original ResearchConceptsThyroid disease historyThyroid diseaseAtrial fibrillationDisease historyThromboembolic eventsClinical outcomesOutcomes of atrial fibrillationHistory of thyroid diseaseBaseline characteristics of patientsCox modelBenefits of apixabanOther Thromboembolic EventsCharacteristics of patientsEffects of anticoagulantsAdjusted hazard ratiosBaseline characteristicsCompare outcomesHazard ratioThyroidApixabanPatientsRandomized treatmentWarfarinHypothyroidismDisease
2017
Relationship Between Peak Troponin Values and Long‐Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes
Goldstein S, Newby L, Cyr D, Neely M, Lüscher T, Brown E, White H, Ohman E, Roe M, Hamm C. Relationship Between Peak Troponin Values and Long‐Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes. Journal Of The American Heart Association 2017, 6: e005334. PMID: 28400368, PMCID: PMC5533023, DOI: 10.1161/jaha.116.005334.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedBiomarkersChi-Square DistributionClopidogrelDouble-Blind MethodFemaleHumansKaplan-Meier EstimateLinear ModelsMaleMiddle AgedMultivariate AnalysisNon-ST Elevated Myocardial InfarctionPlatelet Aggregation InhibitorsPrasugrel HydrochlorideProportional Hazards ModelsRisk FactorsTiclopidineTime FactorsTreatment OutcomeTroponinUp-RegulationConceptsNon-ST-segment elevation ACS patientsLong-term ischemic eventsACS patientsDiabetes mellitus prevalenceTroponin levelsBody mass indexStatistically significant heterogeneityGRACE risk scoreHeterogeneity of treatment effectsIschemic eventsIndex ACS eventACS eventsNon-ST-segment elevation ACSMedically managed patientsComposite end pointLong-term outcomesMass indexTreatment effectsRisk scorePeak troponin valuesPercutaneous coronary interventionSignificant heterogeneityStatistically significant differenceManaging patientsPeak troponin